Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Peptide Stacks
Research-backed peptide stacks for fat loss, recovery, longevity, and performance. Each entry covers mechanism interactions, evidence level, and individual compound profiles. Not protocols — not dosing guidance.
Hexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
A synergistic combination of a GHRH analog (Sermorelin) and a ghrelin-mimetic GHRP (GHRP-2) that activates two distinct receptor pathways to amplify natural growth hormone release. Commonly researched for supporting body composition, recovery, and age-related GH decline.
An advanced triple-secretagogue stack designed to maximally stimulate endogenous GH release through three complementary mechanisms. CJC-1295 extends GHRH signalling, Ipamorelin provides selective ghrelin-receptor stimulation with a clean side-effect profile, and GHRP-6 adds additional pulse amplitude alongside appetite stimulation. This combination is popular in performance communities seeking the highest attainable GH output without exogenous HGH.
A foundational growth hormone secretagogue stack pairing a GHRH analogue (CJC-1295) with a selective GH secretagogue (Ipamorelin). CJC-1295 amplifies GH output by extending GHRH signal duration, while Ipamorelin triggers additional GH pulses through the ghrelin receptor with minimal cortisol or prolactin elevation. Together they produce synergistic, more physiologically natural GH release compared to either peptide alone.
A popular performance and recovery stack combining the GH secretagogue synergy of CJC-1295 and Ipamorelin with BPC-157's direct tissue healing and anti-inflammatory effects. The GH component supports protein synthesis, body composition, and systemic recovery, while BPC-157 targets localised tissue repair, tendon and ligament healing, and gut integrity. This three-peptide combination is widely used by athletes seeking both systemic anabolic support and targeted injury recovery simultaneously.
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
A widely used injury recovery stack combining BPC-157's potent localised tissue healing with TB-500's systemic cell migration and angiogenesis support via thymosin beta-4 activity. BPC-157 focuses on tendon, ligament, and gut repair through growth factor receptor upregulation, while TB-500 accelerates broader tissue repair and reduces inflammation. The two peptides address complementary steps in the healing cascade with minimal mechanistic overlap.
KPV, a C-terminal tripeptide fragment of alpha-MSH, is researched for its MC1R-mediated anti-inflammatory action specifically in the gastrointestinal tract. Larazotide acetate (AT-1001) is investigated as a tight-junction regulator that reduces intestinal permeability. The combination is explored for supporting gut barrier integrity and managing mucosal inflammatory signaling.
A broad-spectrum immune support stack combining thymosin alpha-1's T-cell maturation and adaptive immune enhancement with LL-37's antimicrobial peptide activity and innate immune modulation. Thymosin alpha-1 is clinically used to restore immune competence in immunocompromised patients by promoting dendritic cell and NK cell activity, while LL-37 provides direct antimicrobial action and regulates inflammatory signalling. The stack targets both adaptive and innate arms of immunity through complementary mechanisms.
A targeted wound healing and skin regeneration stack pairing BPC-157's systemic tissue repair signalling with GHK-Cu's potent collagen synthesis and dermal remodelling properties. BPC-157 accelerates deep tissue, tendon, and vascular healing, while GHK-Cu stimulates fibroblast activity, antioxidant gene expression, and extracellular matrix renewal. The combination addresses both deep structural integrity and surface skin quality through distinct mechanisms.
A complementary pairing of TB-500's systemic anti-inflammatory and actin-binding tissue-repair properties with PEG-MGF's localized satellite cell activation. Commonly researched for accelerating recovery from muscle injury and supporting lean tissue regeneration.
A longevity-focused stack pairing GHK-Cu's tissue rejuvenation and antioxidant gene activation with epithalon's proposed telomere-lengthening and pineal gland regulatory effects. GHK-Cu resets gene expression toward a younger phenotype by activating antioxidant and anti-inflammatory gene networks, while epithalon is proposed to slow cellular ageing by stimulating telomerase and regulating circadian and neuroendocrine function. The combination addresses anti-aging at both the cellular replication and tissue maintenance levels.
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
Both Thymalin and Epithalon are short bioregulatory peptides developed by Vladimir Khavinson and studied across decades of Russian gerontological research. Thymalin is associated with thymic peptide function and immune regulation in aging populations; Epithalon with pineal peptide activity, melatonin normalization, and telomere elongation. The combination is commonly referenced in longevity research for its dual immune-modulating and anti-aging mechanistic rationale.
Dihexa is researched as a potent hepatocyte growth factor (HGF/c-Met) modulator that promotes synaptogenesis and spatial memory. Semax, an ACTH analog, is investigated for BDNF upregulation and neuroprotective signaling in the brain. The combination is explored for its complementary routes to memory consolidation and cognitive resilience.
A complementary nootropic stack from Russian peptide research pairing Selank's anxiolytic and stress-modulating properties with Semax's BDNF-upregulating and cognitive-enhancing effects. Selank reduces anxiety and stabilises mood via modulation of the enkephalin system and GABAergic tone, while Semax enhances focus, memory consolidation, and neuroprotection through BDNF and ACTH-related pathways. Together they aim to eliminate cognitive friction while amplifying mental output.
MK-677 (ibutamoren), an orally active ghrelin mimetic, is commonly researched for improving REM and slow-wave sleep alongside GH pulse enhancement. Combined with Epithalon's research into pineal peptide bioregulation and telomere dynamics, this stack is explored for both sleep quality and longevity-related outcomes.
A sleep and stress-reduction stack combining DSIP's direct sleep-promoting and sleep architecture-improving properties with Selank's daytime anxiolytic and mood-stabilising effects. DSIP is proposed to increase slow-wave delta sleep and normalise circadian sleep patterns by modulating hypothalamic sleep-wake centres, while Selank reduces anxiety, cortisol reactivity, and cognitive stress load that often prevents sleep onset. The combination targets both the quality of sleep and the psychological barriers to achieving it.
Melanotan II is researched as a melanocortin receptor agonist with centrally mediated effects on arousal and sexual motivation through MC3R and MC4R pathways. Gonadorelin, a synthetic GnRH analog, is investigated for stimulating pulsatile LH and FSH release to support the hypothalamic-pituitary-gonadal (HPG) axis. The combination addresses sexual health through complementary central arousal signaling and hormonal baseline support.
A central and upstream sexual function stack combining PT-141's direct melanocortin receptor activation for arousal with kisspeptin-10's hypothalamic stimulation of the HPG axis. PT-141 enhances sexual desire and performance at the CNS level independent of vascular mechanisms, while kisspeptin-10 drives pulsatile LH and GnRH release to support the hormonal underpinning of libido. The two peptides target sexual function at different levels of the neuroendocrine hierarchy.